Overview of recombinant monoclonal antibody development platform
DimAb® recombinant monoclonal antibody development platform is considered as a technology revolution for monoclonal antibody development. Compared with traditional hybridoma based monoclonal antibody development platform, this new technology platform can directly obtain IgG gene sequences from immunoreactive B cells without the need of hybridoma fusion. From our data, we can easily isolate more than 1000 immunoreactive B cell clones from a single immunized animal. The success rate for downstream application is far higher than the traditional hybridoma platform.
With large number of positive clones, it will give us better chance to screen out monoclonal antibodies with high specificity, high sensitivity and high affinity. Because we can directly obtain IgG genes, we can also directly edit, optimize and identify antibodies for downstream applications, such as humanization of antibody, affinity maturation, construction of cell lines, etc.
Since the DimAb® preparation process is no longer dependent on the availability of myeloma fusion partner, there is a possibility of developing monoclonal antibody from different kinds of animal species. With this technology, DimAb® will offer a unique solution for those antigens with high homology and weak immunogenicity by using different host for immunization. At present, we have optimized the high throughput developmental process on rabbit and mouse derived recombinant monoclonal antibodies.
DimAb® recombinant monoclonal antibody preparation platform
Comparison Between DimAb® Platform and Hybridoma Platform
|Comparison Items||DimAb® antibody preparation platform||Hybridoma Platform|
|Success Rate||High project success rate（80-90%）||Low project success rate（50%）|
|Storage mode||The antibody gene sequence is obtained directly, and the antibody information is easy to store and transmit||The cost of hybridoma cell preservation is very high, which requires a lot of liquid nitrogen and cell storage equipment|
|Screening efficiency||In theory, every antibody secretion B cells can be screened and isolated||The fusion efficiency of hybridoma is a limiting factor, and many B cells cannot form stable fusion clones|
|Antibody quality||Recombinant antibody with DNA sequence available||Hybridoma cells are unstable, which may lead to the loss of antibody genes|
|Availability of mAbs from different kinds of animal species||Recombinant mAbs from different kinds of animal species can be obtained||Due to intellectual property, only mouse monoclonal antibodies are widely avialble|
|Preparation process||The preparation process is fast and antibody genes can be obtained directly||The quality and stability of antibodies secrected from hybridoma cells are highly unstable. It is necessary to clone antibody gene alone to establish cell lines|
|Animal ethics||No need to kill animals||Need to sacrifice animal to obtain splenocytes|